Remeron® (mirtazapine) Tablets are indicated for the treatment of major depressive disorder. Evidence gathered in preclinical studies suggests that mirtazapine enhances central noradrenergic and serotonergic activity.

SARAFEM is indicated for the treatment of premenstrual dysphoric disorder (PMDD). The efficacy of fluoxetine in the treatment of PMDD was established in 3 placebo-controlled trials. The effectiveness of SARAFEM in long-term use, that is, for more than 6 months, has not been systematically evaluated in controlled trials.

Surmontil is an antidepressant with an anxiety-reducing sedative component to its action. It is indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states.

Tofranil, imipramine hydrochloride USP, the original tricyclic antidepressant, is a member of the dibenzazepine group of compounds. It is indicated for the relief of symptoms of depression. It may be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests.

Tofranil-PM (imipramine pamoate), is a tricyclic antidepressant, available as capsules for oral administration. For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident.

Trazodone hydrochloride tablets are indicated for the treatment of depression. The efficacy of trazodone has been demonstrated in both inpatient and outpatient settings and for depressed patients with and without prominent anxiety.

Protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients.